11 min read
Monthly FDA Guidance and Regulatory News Review - September 2026
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
Learn More →
Meet Veristat at the Orphan Drug Congress, 14-17 November 2022
Whether you have a compound and need to get started on your IND, or want to recruit patients quickly to get your early phase trials running or just need medical writing or biostatistical support for your programs - Veristat can help. We provide impactful solutions on both a full-service or functional service basis.
Veristat team members Mariska van der Heijden, VP of European Sales and Balma Gil Gimeno, Business Development Director, will be at the venue— ready to listen to your needs and share Veristat’s expertise in orphan drug development.
If you’d like to talk to us, simply schedule a meeting by filling out the form on the right. Find out how we can help you advance your next clinical trial or regulatory submission to a successful outcome or learn more about our capabilities.
Website: https://www.terrapinn.com/conference/world-orphan-drug-congress/index.stm
11 min read
Oct 21, 2026 Veristat Blog
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
8 min read
Sep 21, 2026 Veristat Blog
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...